» Articles » PMID: 23317504

Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-specific Targeting

Overview
Journal Mol Cell
Publisher Cell Press
Specialty Cell Biology
Date 2013 Jan 16
PMID 23317504
Citations 206
Authors
Affiliations
Soon will be listed here.
Abstract

Bromodomain-containing protein 4 (Brd4) is an epigenetic reader and transcriptional regulator recently identified as a cancer therapeutic target for acute myeloid leukemia, multiple myeloma, and Burkitt's lymphoma. Although chromatin targeting is a crucial function of Brd4, there is little understanding of how bromodomains that bind acetylated histones are regulated, nor how the gene-specific activity of Brd4 is determined. Via interaction screen and domain mapping, we identified p53 as a functional partner of Brd4. Interestingly, Brd4 association with p53 is modulated by casein kinase II (CK2)-mediated phosphorylation of a conserved acidic region in Brd4 that selectively contacts either a juxtaposed bromodomain or an adjacent basic region to dictate the ability of Brd4 binding to chromatin and also the recruitment of p53 to regulated promoters. The unmasking of bromodomains and activator recruitment, concurrently triggered by the CK2 phospho switch, provide an intriguing mechanism for gene-specific targeting by a universal epigenetic reader.

Citing Articles

BRD4 Induces Esophageal Squamous Cell Carcinoma Progression via the Wnt/β-catenin Pathway.

Niu H, Wei H, Zhou X, Liu Y, Yang L, Wang Q Biochem Genet. 2025; .

PMID: 39903433 DOI: 10.1007/s10528-025-11043-0.


BET inhibitor and CDK4/6 inhibitor synergistically inhibit breast cancer by suppressing BRD4 stability and DNA damage repair.

Chi S, Wei F, Li Y, Yu L, Ma C, Fang Y Transl Oncol. 2024; 51:102212.

PMID: 39591896 PMC: 11629338. DOI: 10.1016/j.tranon.2024.102212.


Phosphorylation by JNK switches BRD4 functions.

Devaiah B, Singh A, Mu J, Chen Q, Meerzaman D, Singer D Mol Cell. 2024; 84(22):4282-4296.e7.

PMID: 39454579 PMC: 11585421. DOI: 10.1016/j.molcel.2024.09.030.


Impact of protein kinase CK2 downregulation and inhibition on oncomir clusters 17 ~ 92 and 106b ~ 25 in prostate, breast, and head and neck cancers.

Kren B, Henzler C, Ahmed K, Trembley J Mol Med. 2024; 30(1):175.

PMID: 39394061 PMC: 11476306. DOI: 10.1186/s10020-024-00937-1.


Resistance of estrogen receptor function to BET bromodomain inhibition is mediated by transcriptional coactivator cooperativity.

Zhang S, Roeder R Nat Struct Mol Biol. 2024; 32(1):98-112.

PMID: 39251822 DOI: 10.1038/s41594-024-01384-6.


References
1.
Phair R, Scaffidi P, Elbi C, Vecerova J, Dey A, Ozato K . Global nature of dynamic protein-chromatin interactions in vivo: three-dimensional genome scanning and dynamic interaction networks of chromatin proteins. Mol Cell Biol. 2004; 24(14):6393-402. PMC: 434243. DOI: 10.1128/MCB.24.14.6393-6402.2004. View

2.
Delmore J, Issa G, Lemieux M, Rahl P, Shi J, Jacobs H . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146(6):904-17. PMC: 3187920. DOI: 10.1016/j.cell.2011.08.017. View

3.
Chiang C . Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4. F1000 Biol Rep. 2010; 1:98. PMC: 2873783. DOI: 10.3410/B1-98. View

4.
Thomas M, Chiang C . E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell. 2005; 17(2):251-64. DOI: 10.1016/j.molcel.2004.12.016. View

5.
Hargreaves D, Horng T, Medzhitov R . Control of inducible gene expression by signal-dependent transcriptional elongation. Cell. 2009; 138(1):129-45. PMC: 2828818. DOI: 10.1016/j.cell.2009.05.047. View